小鼠中内皮启动子效率与特异性的比较揭示Pdgfb阳性造血细胞亚群
该研究用mT/mG报告小鼠和条件性JAK2V617F/WT小鼠比较Pdgfb-iCreERT2、Cdh5(PAC)-CreERT2与Tie2-Cre的内皮重组效率与特异性。成年Cdh5(PAC)-CreERT2小鼠内皮特异性好但需10 mg他莫昔芬;Pdgfb-iCreERT2小鼠注射5 mg他莫昔芬适用于多数内皮研究但肝窦内皮不重组。诱导后2个月所有Pdgfb-iCreERT2;JAK2V617F/WT小鼠发生骨髓增殖性肿瘤,提示Pdgfb-iCreERT2在少量成年造血干细胞中发生重组。
要点
- 成年Cdh5(PAC)-CreERT2小鼠内皮特异性好,但需10 mg他莫昔芬才能持续表达Cre。
- Pdgfb-iCreERT2小鼠注射5 mg他莫昔芬适用于多数内皮研究,但肝窦内皮不重组。
- Pdgfb-iCreERT2在少量成年造血干细胞中发生重组,可致JAK2V617F依赖的骨髓增殖性肿瘤。
核心结论
- 本研究为在选择最佳小鼠品系以研究血管内皮细胞在止血和血栓形成中的作用提供了有用指南。
研究设计与样本
- 使用mT/mG报告小鼠测量重组效率,使用条件性JAK2V617F/WT小鼠评估对造血细胞的特异性。
- 比较Pdgfb-iCreERT2和Cdh5(PAC)-CreERT2与充分表征的Tie2-Cre小鼠。
主要发现
- 成年Cdh5(PAC)-CreERT2小鼠具有内皮特异性,但需要10 mg他莫昔芬才能实现持续的Cre表达。
- 注射5 mg他莫昔芬的Pdgfb-iCreERT2小鼠适用于大多数内皮研究领域,但肝脏研究除外,因为肝窦内皮细胞未发生重组。
- 诱导Cre介导重组后2个月,所有Pdgfb-iCreERT2;JAK2V617F/WT小鼠均发生骨髓增殖性肿瘤,与造血细胞中存在JAK2V617F相关。
- 首次显示Pdgfb-iCreERT2转基因小鼠中Cre介导的重组发生在少量成年造血干细胞中。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Essentials To reliably study the respective roles of blood and endothelial cells in hemostasis, mouse models with a strong and specific endothelial expression of the Cre recombinase are needed. Using mT/mG reporter mice and conditional JAK2V617F/WT mice, we compared Pdgfb-iCreERT2 and Cdh5(PAC)-CreERT2 with well-characterized Tie2-Cre mice. Comparison of recombination efficiency and specificity towards blood lineage reveals major differences between endothelial transgenic mice. Cre-mediated recombination occurs in a small number of adult hematopoietic stem cells in Pdgfb-iCreERT2;JAK2V617F/WT transgenic mice. SUMMARY: Background The vessel wall, and particularly blood endothelial cells (BECs), are intensively studied to better understand hemostasis and target thrombosis. To understand the specific role of BECs, it is important to have mouse models that allow specific and homogeneous expression of genes of interest in all BEC beds without concomitant expression in blood cells. Inducible Pdgfb-iCreERT2 and Cdh5(PAC)-CreERT2 transgenic mice are widely used for BEC targeting. However, issues remain in terms of recombination efficiency and specificity regarding hematopoietic cells. Objectives To determine which mouse model to choose when strong expression of a transgene is required in adult BECs from various organs, without concomitant expression in hematopoietic cells. Methods Using mT/mG reporter mice to measure recombination efficiency and conditional JAK2V617F/WT mice to assess specificity regarding hematopoietic cells, we compared Pdgfb-iCreERT2 and Cdh5(PAC)-CreERT2 with well-characterized Tie2-Cre mice. Results Adult Cdh5(PAC)-CreERT2 mice are endothelial specific but require a dose of 10 mg of tamoxifen to allow constant Cre expression. Pdgfb-iCreERT2 mice injected with 5 mg of tamoxifen are appropriate for most endothelial research fields except liver studies, as hepatic sinusoid ECs are not recombined. Surprisingly, 2 months after induction of Cre-mediated recombination, all Pdgfb-iCreERT2;JAK2V617F/WT mice developed a myeloproliferative neoplasm that is related to the presence of JAK2V617F in hematopoietic cells, showing for the first time that Cre-mediated recombination occurs in a small number of adult hematopoietic stem cells in Pdgfb-iCreERT2 transgenic mice. Conclusion This study provides useful guidelines for choosing the best mouse line to study the role of BECs in hemostasis and thrombosis.
引用
- Kilani B, Gourdou-Latyszenok V, Guy A, et al. Comparison of endothelial promoter efficiency and specificity in mice reveals a subset of Pdgfb-positive hematopoietic cells. J Thromb Haemost. 2019. PMID: 30801958. doi:10.1111/jth.14417
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。